Frequently Asked Questions

AlphaRose is a Public Benefit Corporation building the first scalable, repeatable platform for ultra-rare genetic disease — taking children from variant identification to dosing in months instead of years.

Our PBC charter binds us to deliver therapy to every eligible patient, not only those with commercial viability. The platform — not the drug — is the asset.

For the 95% of rare diseases without an approved therapy, traditional pharma economics simply don’t work. AlphaRose makes the economics of one-patient programs sustainable.

AlphaRose was co-founded by Casey McPherson — a musician, songwriter, and rare-disease parent — alongside scientific and operational leaders from Ionis, Stoke, and Boston Children’s.

ASOs are short, single-stranded synthetic nucleic acids that bind to RNA to modulate gene expression — increasing, decreasing, or correcting splicing of a target transcript.

ASOs are reversible, dose-controllable, manufacturable on a fixed timeline, and have an established regulatory path for N-of-1 use — making them uniquely deployable at scale today.

We use AI for variant impact prediction, splice site modeling, sequence optimization, and efficacy ranking — turning a 6-month bench cycle into a few days of computation.

Traditional biotechs build one drug for one disease. We build one platform that produces one drug per patient.

A platform-as-a-service for ultra-rare disease — combining clinical-grade infrastructure, automated ASO design, GMP manufacturing, and N-of-1 regulatory packaging.

We standardize what big pharma customizes (the chemistry, the rails, the regulatory shape) and customize what big pharma standardizes (the actual sequence per patient).

Variant call to first dose in roughly 180 days, at a unit economics that scales linearly — not exponentially — with patient count.

Founder & CEO Casey McPherson; Scientific Co-founder Dr. Stanley Crooke; Clinical Lead Dr. Tim Yu, plus a regulatory and operations team drawn from Ionis, Stoke, and Boston Children’s Hospital.

AlphaRose is headquartered in Austin, TX with operations in Houston, TX and Boston, MA.

A PBC structure binds the company to its mission as a fiduciary duty — investors and the board must consider patient impact alongside shareholder returns.

Through platform-licensing arrangements with academic medical centers, foundation-funded N-of-1 programs, and select partnerships with larger biotech.

We work with hospital networks, advocacy foundations, sequencing providers, and select pharma teams that recognize that ultra-rare programs require purpose-built infrastructure.

Yes — particularly with health systems and regulatory authorities open to N-of-1 programs and adaptive trial designs.

Over 7,000 known rare diseases affect more than 300 million children globally — and fewer than 5% have any approved therapy.

Orphan drug designation, breakthrough therapy designation, and emerging N-of-1 IND pathways together create a viable regulatory shape for individual approvals.

A 501(c)(3) founded by Casey McPherson to fund ASO programs for children with ultra-rare disease — and the philanthropic engine that proved the AlphaRose thesis.

Email [email protected] — we respond to every patient family and partner enquiry within one business day.